{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T01:50:46Z","timestamp":1778291446966,"version":"3.51.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T00:00:00Z","timestamp":1633824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T00:00:00Z","timestamp":1633824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s00280-021-04359-2","type":"journal-article","created":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T04:15:00Z","timestamp":1633925700000},"page":"11-20","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Adaptation of lenvatinib treatment in patients with hepatocellular carcinoma and portal vein tumor thrombosis"],"prefix":"10.1007","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6716-2413","authenticated-orcid":false,"given":"Takanori","family":"Mukozu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidenari","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daigo","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihide","family":"Mohri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Go","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoyuki","family":"Yoshimine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Amanuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kojiro","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Ogino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Matsukiyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teppei","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuko","family":"Daido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noritaka","family":"Wakui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mie","family":"Shinohara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Momiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Higai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Igarashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,10]]},"reference":[{"key":"4359_CR1","doi-asserted-by":"publisher","first-page":"638747","DOI":"10.1155\/2014\/638747","volume":"2014","author":"O Tohyama","year":"2014","unstructured":"Tohyama O, Matsui J, Kodama K et al (2014) Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res 2014:638747","journal-title":"J Thyroid Res"},{"issue":"6","key":"4359_CR2","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1002\/cam4.1517","volume":"7","author":"M Matsuki","year":"2018","unstructured":"Matsuki M, Hoshi T, Yamamoto Y et al (2018) Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models. Cancer Med 7(6):2641\u20132653","journal-title":"Cancer Med"},{"issue":"10126","key":"4359_CR3","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S et al (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391(10126):1163\u20131173","journal-title":"Lancet"},{"issue":"3","key":"4359_CR4","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1159\/000492533","volume":"7","author":"M Kudo","year":"2018","unstructured":"Kudo M (2018) Extremely high objective response rate of lenvatinib: its clinical relevance and changing the treatment paradigm in hepatocellular carcinoma. Liver Cancer 7(3):215\u2013224","journal-title":"Liver Cancer"},{"issue":"1","key":"4359_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000487148","volume":"7","author":"M Kudo","year":"2018","unstructured":"Kudo M (2018) Lenvatinib may drastically change the treatment landscape of hepatocellular carcinoma. Liver Cancer 7(1):1\u201319","journal-title":"Liver Cancer"},{"issue":"1","key":"4359_CR6","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/cam4.1909","volume":"8","author":"A Hiraoka","year":"2019","unstructured":"Hiraoka A, Kumada T, Kariyama K et al (2019) Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: multicenter analysis. Cancer Med 8(1):137\u2013146","journal-title":"Cancer Med"},{"key":"4359_CR7","first-page":"1","volume":"40","author":"M Qadan","year":"2020","unstructured":"Qadan M, Kothary N, Sangro B, Palta M (2020) The treatment of hepatocellular carcinoma with portal vein tumor thrombosis. Am Soc Clin Oncol Educ Book 40:1\u20138","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"3","key":"4359_CR8","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1159\/000327577","volume":"29","author":"M Kudo","year":"2011","unstructured":"Kudo M, Izumi N, Kokudo N et al (2011) Management of hepatocellular carcinoma in japan: consensus-based clinical practice guidelines proposed by the japan society of hepatology (JSH) 2010 updated version. Dig Dis 29(3):339\u2013364. https:\/\/doi.org\/10.1159\/000327577","journal-title":"Dig Dis"},{"issue":"1","key":"4359_CR9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/hepr.13438","volume":"50","author":"M Kudo","year":"2020","unstructured":"Kudo M, Izumi N, Kubo S et al (2020) Report of the 20th nationwide follow-up survey of primary liver cancer in japan. Hepatol Res 50(1):15\u201346. https:\/\/doi.org\/10.1111\/hepr.13438","journal-title":"Hepatol Res"},{"issue":"2","key":"4359_CR10","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1111\/liv.13988","volume":"39","author":"A Mahringer-Kunz","year":"2019","unstructured":"Mahringer-Kunz A, Steinle V, Duber C et al (2019) Extent of portal vein tumour thrombosis in patients with hepatocellular carcinoma: the more, the worse? Liver Int 39(2):324\u2013331. https:\/\/doi.org\/10.1111\/liv.13988","journal-title":"Liver Int"},{"issue":"1","key":"4359_CR11","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/hep.510290145","volume":"29","author":"JM Llovet","year":"1999","unstructured":"Llovet JM, Bustamante J, Castells A et al (1999) Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 29(1):62\u201367","journal-title":"Hepatology"},{"issue":"2","key":"4359_CR12","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1053\/jhep.2000.9603","volume":"32","author":"E Villa","year":"2000","unstructured":"Villa E, Moles A, Ferretti I et al (2000) Natural history of inoperable hepatocellular carcinoma: estrogen receptors\u2019 status in the tumor is the strongest prognostic factor for survival. Hepatology 32(2):233\u2013238","journal-title":"Hepatology"},{"issue":"1","key":"4359_CR13","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver (2018) EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 69(1):182\u2013236 (Electronic address: easloffice@easloffice.eu)","journal-title":"J Hepatol"},{"issue":"1","key":"4359_CR14","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/hep.29086","volume":"67","author":"JK Heimbach","year":"2018","unstructured":"Heimbach JK, Kulik LM, Finn RS et al (2018) AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 67(1):358\u2013380","journal-title":"Hepatology"},{"issue":"10","key":"4359_CR15","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1111\/hepr.13411","volume":"49","author":"N Kokudo","year":"2019","unstructured":"Kokudo N, Takemura N, Hasegawa K et al (2019) Clinical practice guidelines for hepatocellular carcinoma: the japan society of hepatology 2017 (4th JSH-HCC guidelines) 2019 update. Hepatol Res 49(10):1109\u20131113. https:\/\/doi.org\/10.1111\/hepr.13411","journal-title":"Hepatol Res"},{"issue":"4","key":"4359_CR16","first-page":"2269","volume":"35","author":"H Nagai","year":"2015","unstructured":"Nagai H, Mukozu T, Ogino YU et al (2015) Sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombus. Anticancer Res 35(4):2269\u20132277","journal-title":"Anticancer Res"},{"issue":"3","key":"4359_CR17","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/RUQ.0000000000000355","volume":"34","author":"N Wakui","year":"2018","unstructured":"Wakui N, Nagai H, Matsukiyo Y et al (2018) Effect of hepatic inflammation in chronic hepatitis C infection on fibrosis assessment by arrival time parametric imaging. Ultrasound Q 34(3):128\u2013132","journal-title":"Ultrasound Q"},{"issue":"3","key":"4359_CR18","doi-asserted-by":"publisher","first-page":"373","DOI":"10.7863\/jum.2012.31.3.373","volume":"31","author":"N Wakui","year":"2012","unstructured":"Wakui N, Takayama R, Kanekawa T et al (2012) Usefulness of arrival time parametric imaging in evaluating the degree of liver disease progression in chronic hepatitis C infection. J Ultrasound Med 31(3):373\u2013382","journal-title":"J Ultrasound Med"},{"issue":"4","key":"4359_CR19","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s40477-018-0323-4","volume":"21","author":"N Wakui","year":"2018","unstructured":"Wakui N, Nagai H, Ogino Y et al (2018) Hepatic arterialization can predict the development of collateral veins in patients with HCV-related liver disease. J Ultrasound 21(4):301\u2013308","journal-title":"J Ultrasound"},{"issue":"1","key":"4359_CR20","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30(1):52\u201360","journal-title":"Semin Liver Dis"},{"issue":"10","key":"4359_CR21","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1093\/jnci\/djn134","volume":"100","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Di Bisceglie AM, Bruix J et al (2008) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100(10):698\u2013711","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"4359_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2020.100100","volume":"2","author":"J Gregory","year":"2020","unstructured":"Gregory J, Dioguardi Burgio M, Corrias G, Vilgrain V, Ronot M (2020) Evaluation of liver tumour response by imaging. JHEP Rep 2(3):100100. https:\/\/doi.org\/10.1016\/j.jhepr.2020.100100","journal-title":"JHEP Rep"},{"key":"4359_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11070952","author":"K Ueshima","year":"2019","unstructured":"Ueshima K, Nishida N, Hagiwara S et al (2019) Impact of baseline ALBI grade on the outcomes of hepatocellular carcinoma patients treated with lenvatinib: a multicenter study. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers11070952","journal-title":"Cancers (Basel)"},{"issue":"8","key":"4359_CR24","doi-asserted-by":"publisher","first-page":"3719","DOI":"10.1002\/cam4.2241","volume":"8","author":"A Hiraoka","year":"2019","unstructured":"Hiraoka A, Kumada T, Atsukawa M et al (2019) Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions-multicenter analysis. Cancer Med 8(8):3719\u20133728","journal-title":"Cancer Med"},{"issue":"1","key":"4359_CR25","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1159\/000503031","volume":"9","author":"A Hiraoka","year":"2020","unstructured":"Hiraoka A, Kumada T, Fukunishi S et al (2020) Post-progression treatment eligibility of unresectable hepatocellular carcinoma patients treated with lenvatinib. Liver Cancer 9(1):73\u201383","journal-title":"Liver Cancer"},{"issue":"1","key":"4359_CR26","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1515\/biol-2020-0101","volume":"15","author":"H Yao","year":"2020","unstructured":"Yao H, Wang Y (2020) Relationship between hemodynamic parameters and portal venous pressure in cirrhosis patients with portal hypertension. Open Life Sci 15(1):981\u2013987. https:\/\/doi.org\/10.1515\/biol-2020-0101","journal-title":"Open Life Sci"},{"key":"4359_CR27","unstructured":"Hui R, Li Z, Liu Z, Liu X, Deng H (2021) The clinical value of color Doppler ultrasonography in measuring the hemodynamics of liver cirrhosis patients' portal and splenic veins. Am J Transl Res 13(3):1692\u20131700. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33841691. Accessed 7 July 2021"},{"issue":"S1","key":"4359_CR28","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/liv.14348","volume":"40","author":"DC Valla","year":"2020","unstructured":"Valla DC (2020) Recent developments in the field of vascular liver diseases. Liver Int 40(S1):142\u2013148. https:\/\/doi.org\/10.1111\/liv.14348","journal-title":"Liver Int"},{"issue":"10\u201311","key":"4359_CR29","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1080\/00365521.2018.1503327","volume":"53","author":"K Endo","year":"2018","unstructured":"Endo K, Oikawa T, Kakisaka K, Tamura A, Ehara S, Takikawa Y (2018) The impact of portal vein thrombosis on the prognosis and liver function of nonmalignant cirrhotic patients. Scand J Gastroenterol 53(10\u201311):1340\u20131346. https:\/\/doi.org\/10.1080\/00365521.2018.1503327","journal-title":"Scand J Gastroenterol"},{"key":"4359_CR30","doi-asserted-by":"publisher","unstructured":"Scheiner B, Stammet P, Pokorny S et al (2018) Anticoagulation in non-malignant portal vein thrombosis is safe and improves hepatic function. Wien Klin Wochenschr. 130(13):446\u2013455. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29916054. https:\/\/doi.org\/10.1007\/s00508-018-1351-y. Accessed 20 July 2021","DOI":"10.1007\/s00508-018-1351-y"},{"issue":"5","key":"4359_CR31","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1254\/fpj.153.242","volume":"153","author":"T Watanabe","year":"2019","unstructured":"Watanabe T, Koyama N (2019) Preclinical study for antitumor mechanism of lenvatinib and clinical studies for hepatocellular carcinoma. Nihon Yakurigaku Zasshi 153(5):242\u2013248","journal-title":"Nihon Yakurigaku Zasshi"},{"issue":"4","key":"4359_CR32","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1002\/hep.21785","volume":"46","author":"M Fernandez","year":"2007","unstructured":"Fernandez M, Mejias M, Garcia-Pras E, Mendez R, Garcia-Pagan JC, Bosch J (2007) Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats. Hepatology 46(4):1208\u20131217","journal-title":"Hepatology"},{"issue":"7","key":"4359_CR33","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1046\/j.1538-7836.2003.00263.x","volume":"1","author":"M Autiero","year":"2003","unstructured":"Autiero M, Luttun A, Tjwa M, Carmeliet P (2003) Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost 1(7):1356\u20131370","journal-title":"J Thromb Haemost"},{"issue":"6","key":"4359_CR34","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1053\/j.gastro.2009.08.068","volume":"137","author":"C Van Steenkiste","year":"2009","unstructured":"Van Steenkiste C, Geerts A, Vanheule E et al (2009) Role of placental growth factor in mesenteric neoangiogenesis in a mouse model of portal hypertension. Gastroenterology 137(6):2112\u20132116","journal-title":"Gastroenterology"},{"issue":"5","key":"4359_CR35","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1002\/hep.24238","volume":"53","author":"C Van Steenkiste","year":"2011","unstructured":"Van Steenkiste C, Ribera J, Geerts A et al (2011) Inhibition of placental growth factor activity reduces the severity of fibrosis, inflammation, and portal hypertension in cirrhotic mice. Hepatology 53(5):1629\u20131640","journal-title":"Hepatology"},{"issue":"3","key":"4359_CR36","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1053\/j.gastro.2003.12.012","volume":"126","author":"M Fernandez","year":"2004","unstructured":"Fernandez M, Vizzutti F, Garcia-Pagan JC, Rodes J, Bosch J (2004) Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice. Gastroenterology 126(3):886\u2013894","journal-title":"Gastroenterology"},{"issue":"4","key":"4359_CR37","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/S0016-5085(99)70074-0","volume":"116","author":"G Kleber","year":"1999","unstructured":"Kleber G, Steudel N, Behrmann C et al (1999) Hepatic arterial flow volume and reserve in patients with cirrhosis: use of intra-arterial Doppler and adenosine infusion. Gastroenterology 116(4):906\u2013914","journal-title":"Gastroenterology"},{"issue":"11","key":"4359_CR38","doi-asserted-by":"publisher","first-page":"e13723","DOI":"10.1111\/ctr.13723","volume":"33","author":"K Sasaki","year":"2019","unstructured":"Sasaki K, McVey JC, Firl DJ et al (2019) Sufficient hepatic artery flow compensates for poor portal vein flow after liver transplantation in patients with portal vein thrombosis. Clin Transpl 33(11):e13723. https:\/\/doi.org\/10.1111\/ctr.13723","journal-title":"Clin Transpl"},{"key":"4359_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9103346","author":"R Chung","year":"2020","unstructured":"Chung R, Tyebally S, Chen D et al (2020) Hypertensive cardiotoxicity in cancer treatment-systematic analysis of adjunct, conventional chemotherapy, and novel therapies-epidemiology, incidence, and pathophysiology. J Clin Med. https:\/\/doi.org\/10.3390\/jcm9103346 (E3346 [pii])","journal-title":"J Clin Med"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-021-04359-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-021-04359-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-021-04359-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T17:03:07Z","timestamp":1641488587000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-021-04359-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,10]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["4359"],"URL":"https:\/\/doi.org\/10.1007\/s00280-021-04359-2","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,10]]},"assertion":[{"value":"19 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the ethics committee of Toho University Medical Center, Omori Hospital (approval number M20021) and was performed in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All authors have approved the manuscript and agree with its submission to Cancer Chemotherapy and Pharmacology.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}